Latest revenue
$171.2M
as of 2026-03-31
Latest net income
$6.4M
as of 2026-03-31
Net margin
3.8%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Historical multiples
How does AMPH's current valuation compare to its own past?
P/E uses year-end weekly close ÷ (net income ÷ shares outstanding today). Held shares constant at today's count, which understates the per-share earnings improvement from buybacks over the period. PEG uses 5y revenue CAGR as a proxy for EPS growth — close, but not identical (margin expansion or dilution can drive a wedge). Best read as a comparator across companies and industries, not as a precise replica of historical multiples.
Community sentiment
Where do you think AMPH is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $870.4M
- Enterprise value
- $1.31B
- P/E (trailing)
- 8.9×
- Forward P/E
- —
- P/B
- 1.95×
- Dividend yield
- 0.0%
- 52-wk high
- $31.26
- 52-wk low
- $16.64
- Beta
- —
- Shares out
- 44.1M
5-year trend
What this company does
Item 1. Business. Overview We are a bio-pharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. We currently manufacture and sell over 25 products, the overwhelming majority of which are prescription pharmaceuticals. Since December 2018, we have sold our patented Primatene MIST® using a new hydrofluoroalkanes, or HFA, formulation as our sole over-the-counter product. Our largest products by net revenues currently include BAQSIMI® glucagon nasal powder, or BAQSIMI®, Primatene…
AI summary unavailable — showing raw filing excerpt
Generated from AMPH's filing dated 2024-02-29
Key risks
ITEM 1A. RISK FACTORS Except as noted below, there were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026. We must manufacture our drug products at our facilities in conformity with cGMP regulations; failure to maintain compliance with cGMP regulations may prevent or delay the manufacture or marketing of our products or product candidates and may prevent us from gaining approval of our products. All of our products and product candidates for use in clinical studies must be manufactured, packaged, labeled and stored in accordance with cGMP. For our approved…
AI summary unavailable — showing raw filing excerpt
Generated from AMPH's filing dated 2024-02-29
Profitability
Gross margin
49.5%
3.2%Operating margin
19.5%
30.5%Net margin
13.6%
37.5%Return on equity
13.4%
46.3%Return on assets
6.0%
40.5%Leverage
Debt / equity
1.22×
16.5%Long-term debt / equity
0.83×
11.6%Debt / assets
55.1%
7.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $171.2M | +0.4% | $6.4M | -74.6% | 3.8% |
Q4 2025 2025-12-31 | $183.1M | -1.8% | $24.4M | -35.7% | 13.3% |
Q3 2025 2025-09-30 | $191.8M | +0.3% | $17.4M | -57.1% | 9.0% |
Q2 2025 2025-06-30 | $174.4M | -4.4% | $31.0M | -18.2% | 17.8% |
Q1 2025 2025-03-31 | $170.5M | -0.8% | $25.3M | -41.4% | 14.8% |
Q4 2024 2024-12-31 | $186.5M | — | $38.0M | — | 20.4% |
Q3 2024 2024-09-30 | $191.2M | +5.9% | $40.4M | -17.9% | 21.1% |
Q2 2024 2024-06-30 | $182.4M | +25.2% | $37.9M | +45.3% | 20.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AMPH — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$982.9K
Net activity
−$982.9K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AMPH
Institutional value
$357.8M
Total shares held
19.2M
Distinct holders
134
-99 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.4M | $106.2M | -40.7K (-0.7%) | Trimmed |
| 2 | DIMENSIONAL FUND ADVISORS LP | 2.0M | $39.7M | +228.3K (+12.7%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $30.2M | — | New |
| 4 | TD ASSET MANAGEMENT INC | 1.5M | $30.2M | -422.0K (-21.5%) | Trimmed |
| 5 | Boston Trust Walden Corp | 944.8K | $18.5M | -142.5K (-13.1%) | Trimmed |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 787.8K | $15.4M | — | New |
| 7 | Invesco Ltd. | 604.8K | $11.8M | +103.4K (+20.6%) | Added |
| 8 | SYSTEMATIC FINANCIAL MANAGEMENT LP | 452.9K | $8.9M | +17.3K (+4.0%) | Added |
| 9 | UBS Group AG | 420.3K | $8.2M | +163.6K (+63.8%) | Added |
| 10 | ROYCE & ASSOCIATES LP | 406.2K | $8.0M | +53.9K (+15.3%) | Added |
| 11 | Bridge City Capital, LLC | 335.1K | $6.6M | +99.6K (+42.3%) | Added |
| 12 | DENALI ADVISORS LLC | 266.5K | $5.2M | +54.7K (+25.8%) | Added |
| 13 | Bank of New York Mellon Corp | 243.2K | $4.8M | -15.8K (-6.1%) | Trimmed |
| 14 | VANGUARD FIDUCIARY TRUST CO | 231.0K | $4.5M | — | New |
| 15 | PRINCIPAL FINANCIAL GROUP INC | 209.1K | $4.1M | -8.8K (-4.1%) | Trimmed |
| 16 | BNP PARIBAS FINANCIAL MARKETS | 156.1K | $3.1M | +35.2K (+29.1%) | Added |
| 17 | FIRST TRUST ADVISORS LP | 150.6K | $3.0M | +10.3K (+7.3%) | Added |
| 18 | NEW YORK STATE COMMON RETIREMENT FUND | 148.7K | $2.9M | +22.8K (+18.1%) | Added |
| 19 | Universal- Beteiligungs- und Servicegesellschaft mbH | 139.4K | $2.7M | +110.3K (+379.0%) | Added |
| 20 | FRANKLIN RESOURCES INC | 139.3K | $2.7M | +113.3K (+434.9%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AMPH's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.